Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 05, 2022

SELL
$1.05 - $1.36 $7,875 - $10,200
-7,500 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$1.04 - $1.34 $7,800 - $10,050
7,500 New
7,500 $9,000
Q2 2021

Aug 13, 2021

SELL
$1.51 - $2.29 $15,100 - $22,900
-10,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$1.8 - $3.05 $18,000 - $30,500
10,000 New
10,000 $25,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Rgt Wealth Advisors, LLC Portfolio

Follow Rgt Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rgt Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rgt Wealth Advisors, LLC with notifications on news.